MTOR and cancer: Langdon et al. showed that mTOR signaling was inhibited at an early stage with a dual PI3K/mTOR inhibitor, indicating that the dual-targeted inhibitor only prevented cancer progression, and cancer cells still remained viable and could not be treated [40].